Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 14;9(4):e003604.
doi: 10.1136/rmdopen-2023-003604.

Daratumumab for autoimmune diseases: a systematic review

Marie-Therese Holzer  1 , Nikolas Ruffer  2 , Tobias B Huber  3 , Ina Kötter  2   4 , Lennard Ostendorf #  5   6 , Martin Krusche #  2
Affiliations

Daratumumab for autoimmune diseases: a systematic review

Marie-Therese Holzer et al. RMD Open. .

Abstract

Objective: Refractory autoimmune diseases remain a significant challenge in clinical practice and new therapeutic options are needed. This systematic review evaluates the existing reported data on the CD38-targeting antibody daratumumab as a new therapeutic approach in autoantibody-mediated autoimmune diseases.

Methods: A protocolised systematic literature review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was performed. Two databases (Medline and Embase) were searched for suitable studies. Usage of daratumumab in non-oncological or non-transplantation associated diseases with autoimmune pathophysiology was analysed including patient characteristics, therapeutic regimen, adverse events and patient outcome.

Results: 38 publications reporting the clinical course of 83 patients met the inclusion criteria. Daratumumab usage was reported in therapy-refractory cases (median of 5 different previous therapies) in 24 different autoimmune diseases. The median number of applications of daratumumab was 4, mainly via intravenous applications (87%). Concomitant treatment included glucocorticoids in 64% of patients, intravenous immunoglobulins (33%) and rituximab (17%). Remission or improvement of disease was reported in 81% of patients. Autoantibody depletion or reduction was stated in 52% of patients. Death occurred in three patients (3%). Adverse events were reported in 45% of patients including application-associated reaction (20%), infection (19%) and hypogammaglobulinaemia (33%).

Conclusion: Targeting CD38 via daratumumab is a new promising therapeutic option in therapy refractory autoimmune diseases. Efficacy as well as optimal therapeutic regimen and management or prevention of adverse events require further investigation. Therefore, systematic clinical trials of this therapeutic approach are needed.

Keywords: Antibodies; Autoimmune Diseases; Autoimmunity; Therapeutics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow chart showing the selection process of the systematic review.
Figure 2
Figure 2
Clinical outcome of patients with autoimmune disease treated with daratumumab (number of patients).
Figure 3
Figure 3
Autoantibody titre after daratumumab treatment (number of patients). Not applicable=cases without presence of known autoantibody.
See this image and copyright information in PMC

References

    1. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting Cd38 with Daratumumab monotherapy in multiple myeloma. N Engl J Med 2015;373:1207–19. 10.1056/NEJMoa1506348 - DOI - PubMed
    1. Morandi F, Horenstein AL, Costa F, et al. Cd38: A target for Immunotherapeutic approaches in multiple myeloma. Front Immunol 2018;9:2722. 10.3389/fimmu.2018.02722 - DOI - PMC - PubMed
    1. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754–66. 10.1056/NEJMoa1606038 - DOI - PubMed
    1. Santonocito AM, Consoli U, Bagnato S, et al. Flow Cytometric detection of Aneuploid Cd38(++) Plasmacells and Cd19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res 2004;28:469–77. 10.1016/j.leukres.2003.09.015 - DOI - PubMed
    1. Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class Cd38 Monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 2016;9:51.:51. 10.1186/s13045-016-0283-0 - DOI - PMC - PubMed

Publication types

LinkOut - more resources